Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with substantial morbidity. There is considerable inter-patient variability in the pathologic processes that promote AF, and this variability likely has a significant genetic basis. Clinically this is reflected by the observation that anti-arrhythmic drugs and interventional procedures have highly variable efficacy, and this highlights the need for adopting a more efficacious personalized approach. We explore recent advancements in both in silico and stem cell disease models that set the stage for a personalized approach. Specifically we highlight new mechanistic insights in AF; the future role of computational models in planning personalized ablation strategies; the potential role of stem cell models as a preclinical platform for drug development; and the potential to use gene-editing technology to create patient-specific stem cell models. Finally, we introduce the concept of integrating stem cell models with computational modelling to create a novel pipeline for patient-specific drug discovery and development.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, characterized by compromised atrial electromechanical function and increased risk of thrombus formation and stroke. 1 AF is associated with substantial morbidity, 2 and is an independent predictor of mortality. 3 Existing therapies have proven to have only moderate efficacy. Anti-arrhythmic medications often do not maintain sinus rhythm and have ventricular pro-arrhythmic effects. [4] [5] [6] The ventricular pro-arrhythmic effect of CLASS III anti-arrhythmic drugs (AADs) stems from their tendency to prolong the action potential duration (APD) of ventricular cardiomyocytes, which manifests clinically as a prolonged QT interval on the electrocardiogram (ECG). Prolonged APD increases the risk that an early after depolarization (EAD) will trigger Torsades de pointes, a sudden and life threatening heart rhythm disorder. Importantly, some ion channels are expressed selectively in the atria making them attractive pharmacological targets, as they are expected to have less pro-arrhythmic effect on the ventricles. 7, 8 Adding to the difficulty in selecting safe rhythm control medications in AF, the use of Class I AADs after myocardial infarction has been shown to increase mortality in the CAST 9 and CAST-II 10 studies and are therefore contraindicated in patients with ischaemic heart disease. Furthermore, $5% of patients with paroxysmal AF progress to more persistent patterns yearly, 11 which tend to be less responsive to medical and surgical intervention. Even after multiple catheter ablations for persistent AF, up to 48% of patients may have recurrence of AF. 12 AF is a complex disease, characterized by an interplay of processes that act in broad spatial and temporal dimensions that are incompletely understood from an ionic and molecular basis. 13, 14 Disturbances in numerous pathways have been implicated in producing the commonly observed clinical phenotype, and considerable inter-patient variability is thought to exist in the underlying pathological processes responsible for each individual's disease. 15 This variability helps to explain the unpredictability of efficacy and safety of our current standard therapies when faced with any individual patient encounter. This uncertainty provides the rationale for adopting personalized approaches that move away from one-size-fits-all therapy and instead recognize the many distinct pathophenotypes of the disease. This is particularly relevant in AF given our growing understanding of the heritable nature of the disease, and its genetic determinants. This review will discuss recent advancements in computational and stem cell models of AF. It explores their contributions to the mechanistic understanding of AF, including future roles in drug development and personalized therapy.
; however, the conclusions that can be drawn are limited. Animal models are not exactly representative of the ionic and molecular basis of AF in humans as there are significant interspecies differences in the type and density of ion channels, pumps, exchangers, and gap junction proteins. 19 Thus, the mechanistically important parameters (APD and morphology, CV, etc.) can be quite different between species. Furthermore, atrial anatomy is substantially different and the manner in which structural remodelling contributes to AF may be quite different. As a result, the mechanisms of AF in animals are not necessarily analogous to those in humans, and they have not been sufficiently predictive pre-clinical models for drug development.
In silico models are powerful tools for testing hypotheses relating to mechanisms of re-entry as they allow complete control over select ionic and molecular inputs. The tissue-and organ-level effects of modulating the latter inputs can also be examined in fine spatiotemporal detail. Models are also a good platform for studying the contributions of patient-specific structural remodelling to AF initiation (i.e. fibrosis distribution, fibrotic architecture, and atrial dilatation) and there is a likely future role for in silico guided ablation therapy. 20 Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent a promising and powerful tool for the study of heart rhythm disorders, and for determining the safety and efficacy of therapeutics. This model has been successfully used in cardiac electrophysiology to model disease at a single cell level, reliably reproducing the human cardiac electrical phenotype in health and in disease. hiPSC-CM models will predictably become a crucial component of the screening process for pre-clinical AADs. Differentiation protocols are continuing to improve on generating human cardiac tissue that is physiologically representative of the human condition. In theory, these stem cell derived models should be able to robustly capture the effects of novel AAD'swhich inevitably have multiple points of action and orders of magnitude more downstream consequences in a complex biological system. Nevertheless, the complex phenotype of AF can only be fully appreciated in a 3D anatomically comprehensive system, and a simple monolayer stem cell model will not be able to capture structural aspects of the substrate that are important in AF pathogenesis. Populating anatomically representative in silico models with data from stem cell models that are physiologically representative of the ionic and molecular basis of AF could provide this key missing link. Integrating stem cell and computational models could therefore be a new paradigm for studying AF mechanisms as well as for drug discovery, safety screening, and ultimately personalized medicine.
With the advent of gene editing technologies, stem cell models may be able to provide insights into the pathogenic mechanisms of particular genetic variants, which are a critical step in the journey towards truly personalized therapy for AF. The following section will discuss in detail the genetic basis of AF and the potential to utilize this information in disease modelling and targeted therapies.
Genetic determinants of AF
Multiple studies have established that AF is a disease with significant heritability. [21] [22] [23] [24] The genes contributing to AF risk appear to underlie many divergent biological pathways, suggesting significant pathophysiologic heterogeneity within the population. This heterogeneity alludes to potential benefits for a personalized approach to care guided by genotype. A combination of large-scale genome-wide association studies (GWASs), candidate gene screening studies, and the study of rare families demonstrating Mendelian transmission of AF have all contributed to the identification of susceptibility genes.
21,25
Rare coding variants
Since the 1990s, rare families with AF transmitted via Mendelian inheritance patterns have been evaluated with the goal of identifying genetic culprits for the arrhythmia. 26 Investigators have used linkage analysis to identify loci harbouring causal genetic mutations in these families. 27 Largely, culprit genes have coded for ion channels with mutations resulting in gain-or loss-of-function; however, mutations in genes coding for signalling molecules, structural proteins and transcription factors have also been identified. 21 (Table 1) The rare monogenic forms of AF caused by the latter mutations account for only a small fraction of all cases. Patients with familial AF often present at younger ages without any structural heart disease, potentially secondary to an electrically remodelled substrate [28] [29] [30] [31] [32] [33] ; alternatively, these patients are afflicted with rare comorbid familial cardiomyopathies 34, 35 and have dramatic phenotypes not commonly observed in the rest of the population. As such, patients with familial AF may be poorly representative of AF patients in the general population who present at older ages with typical risk factors. It follows that the underlying causes of AF in these rare familial cases may or may not be generalizable to the more common pathophysiologic mechanisms that contribute to non-familial forms of the disease. Arguably, efforts to develop therapies to target dysregulated pathways identified in various familial forms of AF may not result in development of therapies that are effective on a population level. On the positive side, these early and dramatic phenotypes may help elucidate basic mechanisms. Gene variants observed in familial AF may mediate arrhythmogenesis via distinct mechanisms, including impact on APD, cellular hyperexcitability, and CV heterogeneity. The term 'sub-phenotypes' can be used to refer to these distinct mechanistic subgroups ( Figure 1) . 36 Familial AF may lend itself well to a pharmacogenomic approach, in which a patient's genotype is used to guide AAD selection. The foundation for this type of strategy is currently under development. Hayashi et al screened patients for variants in ion channels and then undertook electrophysiologic and bioinformatics analyses to determine if the variant would lead to a gainof-function or loss-of-function. 37 This preliminary work has clear translational potential when considering the selection of antiarrhythmic agent for these patients, and provides for the conceptual framework of personalized medicine. 
Genome wide association studies
Common variations identified by GWAS may account for the majority of genetic factors underlying AF susceptibility. [38] [39] [40] [41] [42] [43] [44] In contrast to high penetrance and rare mutations seen in familial AF, these common variants are generally polymorphisms in non-coding regions of the genome that lead to modestly increased risk of AF development (the largest magnitude of association corresponding to an odds ratio of $1.6 for a SNP within the 4q25 locus). 21 As these variants have generally been identified in non-coding regions, it has been suggested that their causal effect is mediated by their impact on gene expression by altering enhancer or repressor activity. 21 Moreover, since there are often multiple genes that lie within close proximity to a SNP, it has been difficult to identify the true culprit gene(s). In contrast to genes underlying familial AF, genes in proximity to SNPs identified by GWAS, for the most part do not code for ion channels and include a number of transcription factors and structural proteins ( Table 2) . The mechanisms by which mutations in these genes may increase AF risk is much less understood, though insights are gradually being gleaned. [45] [46] [47] [48] Modelling these common variants could potentially lead to additional insights that are applicable to a much broader population than the rare familial variants. Beyond tailoring personalized pharmacotherapies for patients, genetic profiling may play a role in many other aspects. Risk alleles at 4q25 may predict success of AAD therapy 49 as well as response to ablation therapy. [50] [51] [52] In the future, it may be determined that particular alleles have stronger associations with stroke risk which may guide decisions on anticoagulation.
Although genetic factors certainly play a role in development of AF, the majority of patients with AF have a combination of underlying cardiovascular, and non-cardiovascular diseases along with other risk factors. The strong contribution of clinical risk factors and 'environmental' factors may make a personalized approach to AF management based purely on genotype less feasible. A highly effective approach may ultimately require the incorporation of both genotype and clinical risk factors.
4.
In silico models
Ionic models
Whole-heart computational models incorporate data from multiple scales, ranging from sub-cellular (i.e. intracellular calcium handling dynamics) to organ-level (i.e. cardiac geometry) and simulate wave behaviour in complex 3D substrates. Cell-scale mathematical representations of membrane dynamics (i.e. ionic models) form the building blocks for tissue scale and whole-heart arrhythmia simulations.
Ionic models are mathematical representations of membrane dynamics in atrial cardiomyocytes. 53, 54 Multiple atrial ionic models have been developed using data obtained in patch clamp studies of both animal and human atrial tissue samples. Noteworthy human atrial models are the Courtemanche, 55 Advances in disease models of atrial fibrillation Figure 1 Mechanisms of arrhythmia in genetic forms of atrial fibrillation. This figure outlines the unique mechanisms of arrhythmia development in AF patients with monogenic mutations. In the top row, various categories of mutations are listed with a single example from each category. This is not an exhaustive list of the various mutations implicated in familial AF. In the third row, AF subphenotypes are listed as common mechanisms for arrhythmogenesis in familial AF: CV slowing and heterogeneity, enhanced AP repolarization, delayed AP repolarization, and cellular hyperexcitability. (A) Defects in structural proteins. As an example, a heterozygous p.Glu11Lys mutation in the atrial-specific myosin light chain is depicted. Dysfunctional atrial-specific myosin light chain leads to disruption of sarcomeric structure and ultimately to progressive dilation and fibrosis. This causes conduction velocity slowing and heterogeneity and sets up the substrate for re-entry. (B) Decreased Gap Junction Conduction. Somatic mutations in GJA5 have been described that either impair gap junction assembly or electrical coupling. A gap junction protein is depicted with impaired electrical coupling. There is an inhomogenous distribution of defective gap junction proteins within the atria leading to CV heterogeneity and ultimately forming the substrate for reentry. (C) Increased potassium current. Gain of function mutation resulting in increased repolarizng potassium current is depicted. Enhanced AP repolarization results in shortened effective refractory period. As wavelength = CV Â ERP, a shortened ERP results in smaller wavelengths of re-entry and therefore it is more likely for the atria to accommodate multiple reentrant circuits, thereby maintaining the arrhythmia -a concept that is consistent with the multiple wavelet hypothesis. (D) Decreased potassium current. Loss of function mutation resulting in decreased repolarizing potassium current is depicted. Delayed AP repolarization results in increased APD, which facilitates EADs. Frequent EADs may trigger polymorphic atrial tachycardias with subsequent degeneration to atrial fibrillation -a phenomenon previously coined as 'atrial torsade de pointes'. (E) Hyperpolarizing shift in sodium channel inactivation. A loss of function SCN5A mutation has been described which results in a hyperpolarizing shift in the midpoint of steady-state inactivation as depicted. This results in fewer sodium channels being available for activation at the cellular resting potential (as they are in closed state inactivation conformation), and the channels that are activated, inactivate more quickly than wildtype. This results in a reduced inward sodium current with slower Phase 1 upstroke and a less positive action potential overshoot. It should be noted that derangements of cardiac metabolism have also been implicated in AF development. 64 Recently, computational modelling approaches have been developed to simulate the effect of metabolic stressors on intracellular signalling pathways. 65 However, at present, it would be very difficult to incorporate simulations like these into organscale models due to their high computational complexity.
Tissue-level modelling
Many important questions can be explored using computational simulations including the source of re-entrant activity within AF (so called AF drivers), the structural and electrophysiological properties of the substrate that promote them and the mechanisms by which they are destabilized and terminate. Wavefront propagation through a layer of electrically coupled atrial cardiomyocytes can be modelled via coupled solution of the ionic equations with the bidomain or monodomain 66 
Organ-level modelling
Considering that AF is a phenomenon that occurs in a 3D substrate, it is difficult to appreciate the complete phenotype unless wave behaviour is observed in an organ-level model that accounts for epicardialendocardial association, fast conducting pathways, anatomically realistic fibre orientation, and the impact of macroscopic structures on wave behaviour.
Organ-level models allow for the incorporation of patient-specific cardiac structure into the model and the ability to explore the mechanisms of AF unique to each individual. High-resolution late gadolinium enhancing magnetic resonance imaging (LGE-MRI) can been used to ascertain the atrial geometry of specific patients as well as each individual's distribution of fibrotic tissue. 3D computer models of the heart can then be constructed via segmentation and interpolation of the MRI scan ( Figure 2) . 72 In vivo MRI cannot easily capture atrial fibre orientation, so use of an atlas heart is often used to assign realistic conductivity tensor values. 73 
The role of fibrosis in AF
Fibrosis is critical player in the pathogenesis of AF. Risk of developing AF correlates with increased fibrosis; the burden of fibrosis predicts the number of re-entrant driver sites 74 ; and increased burden of atrial fibrosis also predicts likelihood of recurrence post ablation. 75 However, the precise mechanisms by which fibrotic tissue regions facilitate initiation and maintenance of AF are not fully understood. Some light has been shed on the arrhythmogenic mechanisms of fibrotic tissue by non-invasive imaging studies that have observed focal drivers of AF to develop on areas bordering fibrosis more frequently than within dense fibrotic regions themselves. 74 Recently, 3D bi-atrial models of 20 patients with persistent AF were reconstructed from preablation in vivo LGE-MRI scans. 76 An action potential model calibrated to match properties of myocytes from patients with chronic AF was used to describe ionic current. 77 Cell and tissue-scale effects caused by fibrotic modelling were added in regions of high LGE. AF was inducible in
Computational modeling studies suggest the changes in the slope of the upstroke and the AP overshoot affect the both calcium and potassium currents with a resultant net increase in inward plateau current and thereby increased APD -a process that is not at all mediated by late/sustained inward sodium current.
(F) Depolarizing shift in sodium channel inactivation. An SCN5A mutation has been described that results in a depolarizing state shift for the midpoint of steady-state inactivation. This means that there is a smaller proportion of channels in a 'closed state inactivation' conformation near the resting membrane potential. The corollary of this is that there is a greater proportion of 'recruitable' sodium channels near resting membrane potential and the threshold for action potential firing is therefore lower, resulting in greater cellular hyperexcitability. Ultimately this increases ectopic activity, providing the trigger for arrhythmia initiation. AP, action potential; APD, action potential duration; CV, conduction velocity; EAD, early afterdepolarization; ERP, effective refractory period; WT, wild-type. 13/20 patient-specific models and was perpetuated by re-entrant drivers that persisted in specific regions with high fibrosis density (FD) (proportion of fibrotic tissue in surrounding area) and entropy (FE) (degree of disorganization). These areas of high FD and FE correspond to regions of high intermingling between fibrotic and non-fibrotic tissue. Interestingly, areas of dense fibrosis characterized by high FD but low FE never harboured re-entrant drivers. 76 Taken together with clinical findings that reentrant drivers form at boundaries of fibrotic areas, 78 these results point towards the intermingling of fibrotic and non-fibrotic tissue as the key factor underlying re-entrant formation, rather than dense fibrotic tissue itself.
It should be noted that epicardial adipose tissue has recently been implicated in fibrotic remodelling of atria. 79, 80 The effect of adipose infiltrates on arrhythmogenicity has subsequently been modelled. 81 In the future, this concept could be extended to AF-specific models.
Modelling ablation
Beyond the exploration of AF initiation and perpetuation mechanisms, there may be a more direct therapeutic role played by computer simulations in the near future. The efficacy of AF ablation may be improved when PVI is combined with ablation strategies that target atrial regions with a high propensity for harbouring rotors-a procedure that is directed by phase singularity mapping. 82 However, such procedures are time intensive, may result in a greater number of ablations than necessary, and could potentially miss locations with high likelihood of rotor formation (i.e. potential latent re-entrant drivers not observed during a particular mapped AF episode). In theory, shorter procedures with higher efficacy and lower complication events could be facilitated if a minimal ablation strategy could be predicted in silico prior to an ablation procedure. In fact, Bayer et al. 83 simulated radiofrequency ablation of areas with high probabilities of rotor formation and demonstrated successful in silico elimination of persistent AF in a left atrial bi-layer model with patient-specific fibrotic remodelling patterns. Importantly, ablations delivered to areas of the atria with low phase singularity density were less effective at terminating the arrhythmia. As proof of concept that in silico models can guide clinical ablation procedures, Zahid et al. 84 performed a double-blinded retrospective study which examined 10 patients who previously underwent pre-procedure LGE-MRI and ablation therapy to treat left post-PVI atrial flutter (LAFL). An automated algorithm based on network theory was used to determine 'minimum cuts', which were defined as the smallest possible cuts that could break the flow network into two distinct pieces. When ablation lesions were simulated based on minimal cut locations, they terminated LAFL in a majority of patients. When compared with lesions guided by entrainment mapping in the actual EP procedures, simulated lesions were in similar positions, used the same strategy of connecting nonconductive tissues (such as previous ablation lesion to valve, or to another previous ablation lesion), and were shorter by nearly two-fold compared with the clinical ablations ( Figure 3) 
Inter-patient variability of the AF substrate
The computational models discussed in the previous section realistically represent contributions of each individual's unique distribution of fibrosis tissue to AF. However, they do not account for inter-patient differences in ion channel densities or myocardial microstructure that also play a role in arrhythmia. In one recent study, Liberos et al. 85 demonstrated significant in silico differences in rotor stabilization related to variability in ion channel densities. The co-authors used a statistical approach to derive a population of atrial ionic variants (n = 173) from a data set of AP biomarkers from 149 AF patients. Rotors were then induced in spherical models of atrial tissue with each AP variant. Models with reduced depolarizing currents (I Na /I CaL ) had increased core meander and more frequent wave collision, leading to AF termination. Transient I CaL blockade was more likely to prompt AF termination in models with reduced I Na and/or I K1 , suggesting that inter-patient variability in Na/K channel expression may underlie variable efficacy of I CaL -blocking drugs. These simulations were conducted in homogenous, geometrically unrealistic models that cannot capture structural aspects that contribute to AF, meaning that the study's conclusions may exaggerate the impact of electrophysiological variability on rotor dynamics, including the response to AADs. Zhao et al. 86 recently created an atrial model from LGE-MRI images and functional mapping of explanted human atria, which captured variation in atrial wall thickness, distribution of transmural fibrosis, and myofiber orientation, all at high resolution. Endocardial mapping of the explanted atria in AF revealed stable re-entrant drivers in areas of intermediate wall thickness, intermediate fibrosis, and twisted myofiber orientation, suggesting a possible microstructural 'fingerprint' for sites of rotor formation. Accompanying simulations predicted re-entrant drivers that anchored to areas with these same microstructural properties, but failed to form when myofiber orientation and fibrosis were removed. Deng et al. 87 explored the potential role of inter-patient differences in APD and/or CV in personalized models reconstructed from LGE-MRI. consistently anchor to regions at boundaries between fibrotic and nonfibrotic atrial myocardium. This was the case regardless of whether simulations were conducted under average (i.e. parameters controlling APD/ CV calibrated to match typical AF-remodelled electrophysiology; EP avg ) or perturbed (i.e. ±10% APD/CV) conditions. Although a subset (35-80%) of rotors seen in models with perturbed APD/CV were in the same locations as those observed in EP avg models, several other rotor anchoring sites were completely new. These results stress that if simulation-based planning of clinical AF ablation procedures is to become a reality, it will be necessary to augment targeting of rotors observed in models with other substrate-based approaches such as ablating a specific subset of boundaries between non-fibrotic and fibrotic tissue, which may prove more robust to intrinsic uncertainty in models. It may be possible to further enhance the predictive value of computational models (e.g. for accurately predicting response to pharmacotherapy) by incorporating patient-specific electrophysiological data, but the process of doing so may be logistically and/or computationally taxing. The obvious barrier to incorporation of these data is the lack of strategies currently available to non-invasively detect patient-specific electrophysiologic parameters. Clearly, it is not reasonable to obtain atrial tissue. In theory, minimally invasive electrophysiological studies could be performed on select patients to determine patient-specific APD, AP morphology, and CV. Validated fitting procedures could be used to incorporate these clinically determined patient data into personalized models. 88 In the future, it may also be possible to detect patient-specific calcium handling abnormalities with minimally invasive strategies. Up until recently, detecting calcium transients relied on fluorescence imaging. However, a role for photoacoustic imaging in mapping calcium transients has been described in. 89 With the development of miniature photoacoustic imaging catheter probes, the possibility of mapping spatiotemporal patterns of calcium transients in select patients could eventually become a reality. 90 This review discusses at length the role of rotors in AF maintenance, the importance of understanding mechanisms of rotor termination for developing effective pharmacologic approaches, and the importance of predicting high-density rotor sites to guide ablation procedures. It should be noted, however, that the existence and relevance of rotors continues to be debated. Some impressions of rotors may be due to technical mapping artefacts. Various approaches have been used to identify rotorsi.e. ECG imaging and focal impulse and rotor modulation (FIRM) mapping-and have yielded discrepant results with regards to the spatiotemporal stability of rotors. There have also been discrepant results between studies evaluating outcomes of FIRM ablations. For an in depth review covering these topics we direct the reader to a recent review by Nattel et al. 91 
Stem cell models
As has been discussed, there is significant interspecies variability with respect to atrial electrophysiology and cardiac anatomy thus limiting the translational potential of using animal modelling to study AF. In the last decade, the use of hiPSC-CMs has begun to play a role in drug screening and modelling of various cardiac diseases (see Supplementary material online, Table S1 ).
Atrial and ventricular cardiomyocyte models
In order to test whether a particular drug is effective in terminating AF without having deleterious consequences in ventricular and/or nodal tissue, it will be necessary to create different models, each enriched in a specific terminal cell type. Human atrial cells possess the ultra-rapid delayed-rectifier K þ current (I Kur ) conducted by Kv1.5 channels
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; acetylcholine-activated inward-rectifying K þ current (I KACh ) carried by the Kir3.1/3.4 heteromultimer; T-type Ca 2þ currents 93, 94 ; and Ca 2þ acti- 95 all of which are largely absent in the ventricles.
Additionally, I CaL current is generated by Cav1.2 and Cav1.3 subunits in the atria, but only by Cav1.2 in ventricular cardiomyocytes. 96 There is a great impetus to develop drugs that are highly specific for these channels, as they would, in theory, have little to no effect on ventricular tissue. However, in order to effectively screen atrial-specific AADs, the latter channels would need to be expressed in atrial hiPSC-CM models and absent from ventricular-like cells.
Early induced cardiomyocyte models generally have not yielded welldelineated populations of a single terminal cell type, instead producing mixed populations of atrial, nodal, and ventricular cells. As protocols for inducing cardiomyocytes improve, the creation of homogeneous hiPSC-CM populations is on the verge of becoming feasible. Recently, both atrial-and ventricular-like cardiomyocytes were derived from human embryonic stem cells (hESCs) via differential modulation of retinoic acid signalling during cellular differentiation. 97 Atrial-like cardiomyocytes recapitulated electrophysiological properties of native human atrial cells well, and expressed known atrial-specific potassium ion channels Kv1.5 and Kir3.1/3.4. Administration of Kv1.5 blocker, XEN-D0101, reduced atrial repolarization in atrial-like cardiomyocytes. Administration of Kir3.1/3.4 blocker, XEN-RO703, reversed carbachol-induced AP shortening in atrial-like cardiomyocytes. These drug effects were not demonstrated in ventricular-like cardiomyocytes, highlighting the potential of atrial-like hESC-CM as a powerful preclinical model for assessing the efficacy and safety of atrial-selective AADs.
Very recently, re-entrant activity was induced in an atrial-like CM monolayer for the first time. The rotors induced in these sheets were comparable to those observed in previous computer simulations and animal studies, validating the use of such preparations as an AF disease model (Figure 4 ). AADs were shown to impact rotor dynamics in a manner consistent with their known mechanism of action. 98 Flecainide, which is known to be an effective AAD for some AF patients, blocks sodium current, resulting in decreased AP upstroke velocity and decreased CV. In atrial-like hiPSC-CM models, the effect of flecainide was consistent with the latter behaviour, resulting in increased cycle length, decreased CV, and reduced wavefront curvature near the rotor core. Late I Na would be expected to shorten the APD; however, this was not observed and may have been in part a consequence of the concurrent potassium channel blocking properties of flecainide. 99 This example highlights the fact that stem cell models can capture unforeseen electrophysiological consequences that arise when complex biological systems are subjected to drugs that have non-specific, multi-target action mechanisms. Although flecainide administration did not terminate arrhythmia, the observed effects of rotor expansion and reduced wavefront curvature are associated with rotor meandering, which could potentially lead to rotor destabilization and termination. Left and right atria differ largely in their gene expression profiles and function, and therefore it would be desirable to create hiPSC-CM models that recapitulate both right and left phenotypes. Transcription factor Pitx2 mediates left-right asymmetry during cardiac development. 100, 101 Conceivably, atrial-like CM's could be produced that have right or left phenotypes by modulating Pitx2 expression.
Stem cell models as a platform for preclinical drug screening
Cardiomyocyte models such as those just described give a very unique opportunity to 'see' the disease phenotype and the differential response to various drugs. Presumably, they will prove to be more predictive of AADs' in vivo efficacy than the single biomarker screening assays currently used. 102 A positive response to an AAD in an AF stem cell model may be rotor termination; however, drug-induced changes to features of the rotor itself, such as wavefront curvature, core size, core meander, and rotational frequency, may serve as markers for rotor stability, and thereby endpoints for evaluating efficacy. Moreover, these metrics may provide insight into the distinct mechanisms by which various AADs operate to destabilize rotors. In silico models may be required to validate the relationship between particular rotor metrics and rotor stability.
Monolayer in silico models could be calibrated to recapitulate wave behaviour observed in stem cell models before and after administration of an AAD. Calibrated drug models could be subsequently applied to heterogenous 3D atrial models. Early termination of a rotor or inability for a rotor to form in an organ scale model would link particular rotor metrics (observable in stem cell/in silico monolayers) to rotor stability in an anatomically accurate substrate. It could be argued that monolayer stem cell models may not lend themselves as easily to high-throughput (HT) screening strategies as the historically used single biomarker assays, given the spatial requirements to produce re-entrant activity and the need for more sophisticated measurements of monolayer/multicellular wave behaviour. However, these re-entrant rhythms have been induced in small well sizes (<1 cm in diameter), and recent automated optical technology is capable of interrogating over 600 multicellular samples Figure 5 Integrating stem cell derived models and in silico models: a novel paradigm for drug discovery, safety, and personalized therapy. The top portion of the figure demonstrates stem cell derived CM sheets, which in theory could be enriched in a specific CM type (atrial, ventricular, or nodal), or harbour a genetic variant of interest. Chemical libraries could be screened to observe the drug effect on these stem cell models in vitro. As demonstrated below, EP measurements from stem cell models could be ascertained from currently available automated technology and be used to calibrate organ-scale drug models. 3D atrial drug models in which AF is unsustainable would be predictive of an efficacious drug candidate. 3D ventricular drug models that are susceptible to Torsades would predict that the drug candidate may be pro-arrhythmic in vivo. Each step in this pipeline is modifiable depending on the population targeted and clinical question being evaluated.
Advances in disease models of atrial fibrillation per hour, 103 so a HT approach may not be out of reach for monolayer models. Recently, a simple and robust cardiomyocyte induction method has been developed which is compatible with both 2D (cell monolayers) and 3D (suspension of embroid bodies) culture formats. The 3D format is likely to be well suited for cost-effective large scale production of hiPSCCMs; although, could likely benefit from additional selection strategies to increase purity of fully differentiated CMs. The 2D format yielded higher purity of CMs (80-95%) and therefore may be most appropriate format for cardiac disease modelling. 104 Additionally, single cell preclinical models may also have strong predictive value for AAD efficacy and safety; and single cell or small CM clusters would unquestionably be amenable to a HT approach. Changes to APD, the presence of EADs and APD alternans may be predictive of AF susceptibility (atrial CM) or vulnerability to Torsades (ventricular CM), and could be used as markers for anti-arrhythmic efficacy and safety in HT screening studies.
Modelling genetic variants
We have discussed at length that AF is a disease with significant heritability even outside of the familial AF population. With the advent of clustered regularly interspaced short palindromic repeats-Cas9 105-107 and other stem cell gene editing technologies it is easy to imagine the creation of many CM tissue models each harbouring different genetic variants along with their isogenic controls. Both rare mutations observed in familial AF as well as the more common risk alleles could be modelled, enabling the study of patient-specific disease mechanisms, and setting the stage for a pharmacogenomic approach to AF. Drug screening using models of rare variants (i.e. gain-of-function ion channels) may yield highly effective and safe therapies for rare patients with familial AF. However, modelling common variants may have implications on a much broader scale. For example, it remains to be understood how genes associated with common risk alleles such as PITX2 may modify risk of AF development. Gene expression analysis and proteomic analysis of these genetic variants could help elucidate the dysregulated pathways underlying AF vulnerability in patients with these risk alleles, and ultimately may lead to the identification of new drug targets and the development of therapeutics that would be broadly effective.
Beyond their role in drug development and discovery, gene edited stem cell models may also be a useful avenue for defining the variablesparticular SNP, drugs being compared, etc.-to maximize the likelihood of designing a clinical trial that would yield a positive result (i.e. clinical trial in a dish). For example, a pair of AADs demonstrating highly variable efficacy in models harbouring a risk allele at 4q25 (i.e. locus associated with PITX2), could inspire a clinical trial for this relatively large AF subpopulation with a high likelihood of producing statistically significant outcomes.
It should be noted that currently, hiPSC-CMs are developmentally immature and do not entirely recapitulate the electrophysiological properties of mature cardiomyocytes. Specifically, hiPSC-CMs have more depolarized resting membrane potentials, spontaneous depolarization during Phase 4, decreased maximum upstroke velocity, and decreased CV. 108 Even small differences in baseline EP properties may result in differential responses to pharmacologic intervention. Syeda et al. 109 demonstrated that flecainide significantly improved arrhythmia suppression in atria with reduced Pitx2c expression, mediated by a modestly more depolarized resting membrane potential in the Pitx2c deficient atria ($1.2 to 2.4 mV more depolarized). Given the present short-comings of hiPSC-CMs, results of screening experiments may still need to be validated in cardiomyocytes or in isolated organs.
Limitations in drug development and proposal of a novel pipeline
Despite significant advances in understanding of disease mechanisms and an ever-increasing number of potential targets for drug development, the FDA approval rate of pharmacological therapies is not reflective of this expansion in potential drug targets and may actually be declining. The latter phenomenon is largely attributable to the high rate (up to 96%) of drug attrition during preclinical and clinical testing. 110, 111 This high attrition rate is in part due to the low specificity of current safety screening assays which results in the exclusion of many candidate drugs that could have been highly effective and safe in human beings. Current screening assays measure the effect of a candidate drug at only one channel, the human ether-a-go-go related gene (hERG) channel, which carries repolarizing potassium current. Blockade of this channel may cause delayed cellular repolarization, which increases the likelihood of an EAD, and development of Torsades. However, since many channels play a role in whether an EAD is triggered or not, looking at hERG activity in isolation will overestimate the risk of many potentially safe medications. Conversely, a drug with low hERG channel activity may be arrhythmogenic in vivo, and would not be identified in this safety screen. The Comprehensive in Vitro Proarrhythmia Assay initiative has resulted in the development of a novel paradigm for screening proarrhythmic risk of preclinical drugs, which is expected to decrease the rate of drug attrition. The premise is to use automated HT patch clamp technology to measure currents from select ion channels carrying I Kr , I Na , I to , I Ks , and I K1 , and use these experimentally determined values to populate in silico model input parameters. The computational model will determine the effects on the ventricular CM action potential and stratify preclinical compounds as having low, medium, or high pro-arrhythmic potential. 112 The concept of using the experimental values from stem cell models to populate input parameters for computational models can be easily extended to many other processes relating to drug discovery, screening, and personalized therapy for AF ( Figure 5 ).
Conclusion
In light of the increasingly recognized genetic basis for AF, the variable pathogenesis of the disease, and the modest and variable efficacy of existing AADs and ablation strategies, it is clear that more personalized approaches need to be adopted to improve the efficacy and safety of AF therapy. AF disease models have played a key role in understanding the patient-specific mechanisms of AF, and there are future roles for computational models to guide personalized ablation strategies as well as for stem cell models to be used as a preclinical platform for personalized drug development. Moreover, stem cell models will be amenable to gene-editing technology, setting the stage for a pharmacogenomic approach to AF therapy. Finally, populating anatomically accurate in silico models with experimentally determined EP measurements from stem cell models would constitute a novel platform for drug discovery, development, and ultimately personalization of AF therapy.
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